Liu Xuemei, Zhang Dajin, Cao Guojun, Yang Guang, Ding Hongmei, Liu Gang, Fan Ming, Shen Beifen, Shao Ningsheng
Beijing Institute of Basic Medical Sciences, Beijing 100850, People's Republic of China.
J Mol Recognit. 2003 Jan-Feb;16(1):23-7. doi: 10.1002/jmr.604.
Bovine thrombin is widely used in clinical wound healing after surgery. There is 85% homology between bovine thrombin and human thrombin, so most antibodies against bovine thrombin cross-react with human thrombin. Rare antibodies against bovine thrombin but not cross-reacting with human thrombin have been reported. RNA ligands (aptamers) have been used to bind to target molecules with sometimes higher specificity than antibodies. Here we report the isolation of aptamers specific for bovine thrombin by systematic evolution of ligands by exponential enrichment (SELEX) from an RNA pool containing a 25-nucleotide randomized region. After seven rounds of selection, two aptamers specific for bovine thrombin were identified with a K(d) of 164 and 240 nM, respectively. Significantly, these aptamers do not bind to human thrombin. Secondary structure prediction revealed potential stem-loop structures for these RNAs. Both RNA aptamers inhibit only bovine thrombin-catalyzed fibrin clot formation in vitro. Competition assay results suggested that the RNA aptamers might bind to the electropositive domain of bovine thrombin, that is, heparin-binding site, instead of fibrinogen-recognition exosite. The resulting bovine-specific thrombin inhibitor might be used in some clinical applications when bovine thrombin activity needs to be contained or in research where human and bovine thrombin need to be distinguished.
牛凝血酶在临床术后伤口愈合中被广泛应用。牛凝血酶与人凝血酶有85%的同源性,因此大多数抗牛凝血酶抗体与人凝血酶会发生交叉反应。已报道有罕见的抗牛凝血酶抗体但与人凝血酶不发生交叉反应。RNA配体(适配体)已被用于结合靶分子,其特异性有时高于抗体。在此,我们报道了通过指数富集配体系统进化技术(SELEX)从一个包含25个核苷酸随机区域的RNA文库中筛选出对牛凝血酶具有特异性的适配体。经过七轮筛选,鉴定出两种对牛凝血酶具有特异性的适配体,其解离常数(K(d))分别为164和240 nM。值得注意的是,这些适配体不与人凝血酶结合。二级结构预测显示这些RNA具有潜在的茎环结构。两种RNA适配体在体外仅抑制牛凝血酶催化的纤维蛋白凝块形成。竞争分析结果表明,RNA适配体可能结合牛凝血酶的正电结构域,即肝素结合位点,而非纤维蛋白原识别外位点。所得的牛特异性凝血酶抑制剂可用于需要抑制牛凝血酶活性的某些临床应用中,或用于需要区分人凝血酶和牛凝血酶的研究中。